The estimated Net Worth of Timothy R Wright is at least $16.6 million dollars as of 9 June 2022. Mr. Wright owns over 112,000 units of MiMedx Inc stock worth over $10,593,096 and over the last 5 years he sold MDXG stock worth over $904,579. In addition, he makes $5,069,350 as Chief Executive Officer et Director at MiMedx Inc.
Timothy has made over 4 trades of the MiMedx Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently he sold 112,000 units of MDXG stock worth $420,000 on 9 June 2022.
The largest trade he's ever made was selling 112,000 units of MiMedx Inc stock on 9 June 2022 worth over $420,000. On average, Timothy trades about 32,057 units every 37 days since 2019. As of 9 June 2022 he still owns at least 1,711,324 units of MiMedx Inc stock.
You can see the complete history of Mr. Wright stock trades at the bottom of the page.
Timothy R. Wright serves as Chief Executive Officer, Director of the Company. joined the Company as its Chief Executive Officer on May 13, 2019. Mr. Wright has more than 30 years of experience in the pharmaceutical, biotech and medical devices industries. Most recently, Mr. Wright served as a Partner at Signal Hill Advisors, LLC, a consulting practice, since February 2011. Mr. Wright served as President and Chief Executive Officer of M2Gen Corp., a privately held cancer and health informatics company, between July 2017 and September 2018. Prior to M2Gen Corp., Mr. Wright served as Executive Vice President, Mergers and Acquisitions, Strategy and Innovation for Teva Pharmaceutical Industries Ltd. (“Teva”), a pharmaceutical company specializing in generic medicines, from April 2015 until August 2017. Before Teva, Mr. Wright was the founding partner of The Ohio State University Comprehensive Cancer Drug Development Institute. Mr. Wright also served as Chairman, Interim Chief Executive Officer and a director of Curaxis Pharmaceutical Corporation (“Curaxis”), a pharmaceutical company specializing in the development of drugs for the treatment of Alzheimer’s disease and various cancers, from July 2011 to July 2012. Curaxis had been experiencing financial difficulties prior to Mr. Wright’s tenure and, as a result, the company filed for Chapter 11 bankruptcy in July 2012. Mr. Wright has been a director of Agenus, Inc. (NASDAQ: AGEN), an immune oncology company, since 2006 and its lead director since 2009. Mr. Wright also serves as Chairperson of The Ohio State University Comprehensive Cancer Center Drug Development Institute, serves as director of The Ohio State Innovation Foundation and sits on The Ohio State University College of Pharmacy Dean’s Corporate Council. Over his career, Mr. Wright has served on boards of directors in North America, Europe and Asia. Mr. Wright earned a Bachelor’s of Science in Marketing from The Ohio State University.
As the Chief Executive Officer et Director of MiMedx Inc, the total compensation of Timothy Wright at MiMedx Inc is $5,069,350. There are no executives at MiMedx Inc getting paid more.
Timothy Wright is 62, he's been the Chief Executive Officer et Director of MiMedx Inc since 2019. There are 11 older and 11 younger executives at MiMedx Inc. The oldest executive at MiMedx Group, Inc is Neil Yeston, 77, who is the Independent Director.
Timothy's mailing address filed with the SEC is 1775, West Oak Commons Court Northeast, Marietta, Cobb, Georgia, 30062, United States.
Over the last 15 years, insiders at MiMedx Inc have traded over $15,165,698 worth of MiMedx Inc stock and bought 1,553,718 units worth $4,191,559 . The most active insiders traders include Fund Management Ltd.Okumus ..., Steve Gorlin et Parker H Petit. On average, MiMedx Inc executives and independent directors trade stock every 48 days with the average trade being worth of $487,865. The most recent stock trade was executed by William Frank Iv Hulse on 13 March 2024, trading 20,381 units of MDXG stock currently worth $162,029.
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a semi-permeable protective barrier membrane product used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, pressure ulcers, and burns; AmnioFix, a semi-permeable protective barrier membrane product for the treatment of wounds related to surgical procedures; EpiCord and AmnioCord that are dehydrated human umbilical cord allografts intended for homologous applications; and AmnioFill that consists of particles of connective tissue matrix derived from placental disc and placental membranes. The company's products have applications primarily in the areas of wound care, burn, surgical, and non-operative sports medicine sectors of healthcare. It also sells allografts for dental applications on an original equipment manufacturer basis. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. is headquartered in Marietta, Georgia.
MiMedx Inc executives and other stock owners filed with the SEC include: